217 related articles for article (PubMed ID: 23313032)
1. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.
Weight CJ; Kim SP; Jacobson DJ; McGree ME; Boorjian SA; Thompson RH; Leibovich BC; Karnes RJ; St Sauver J
Eur Urol; 2013 Jun; 63(6):1021-7. PubMed ID: 23313032
[TBL] [Abstract][Full Text] [Related]
2. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
3. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
4. Lower urinary tract symptoms-Benign prostatic hyperplasia may increase the risk of subsequent inguinal hernia in a Taiwanese population: A nationwide population-Based cohort study.
Wu YH; Juan YS; Shen JT; Wang HS; Jhan JH; Lee YC; Geng JH
PLoS One; 2020; 15(6):e0234329. PubMed ID: 32511262
[TBL] [Abstract][Full Text] [Related]
5. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
6. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
7. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
Patel DN; Feng T; Simon RM; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Roehrborn C; Andriole GL; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):238-244. PubMed ID: 29795141
[TBL] [Abstract][Full Text] [Related]
8. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
[No Abstract] [Full Text] [Related]
9. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
10. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
11. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series.
Malling B; Røder MA; Lindh M; Frevert S; Brasso K; Lönn L
Cardiovasc Intervent Radiol; 2019 Oct; 42(10):1405-1412. PubMed ID: 31062066
[TBL] [Abstract][Full Text] [Related]
12. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
13. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
14. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KN; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
BJU Int; 2008 Dec; 102(11):1629-33. PubMed ID: 18710456
[TBL] [Abstract][Full Text] [Related]
16. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
Welliver C; Feinstein L; Ward JB; Kirkali Z; Martinez-Miller EE; Matlaga BR; McVary K
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):269-273. PubMed ID: 34545201
[TBL] [Abstract][Full Text] [Related]
17. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
18. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
19. Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population.
Walz J; Suardi N; Hutterer GC; Perrotte P; Gallina A; Bénard F; Valiquette L; McCormack M; Graefen M; Montorsi F; Karakiewicz PI
J Endourol; 2008 Feb; 22(2):369-76. PubMed ID: 18294044
[TBL] [Abstract][Full Text] [Related]
20. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
